Skip to Content
Merck
  • Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril).

Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril).

The Journal of toxicological sciences (1996-11-01)
E J McGuire, J A Anderson, A W Gough, J R Herman, D G Pegg, J C Theiss, F A de la Iglesia
ABSTRACT

Acute, subacute, and chronic toxicity studies, carcinogenicity bioassays, and reproductive and genetic toxicology studies were performed with quinapril, an ACE inhibitor used in the treatment of hypertension. Acute toxicity is minimal in rodents, and repeated dosing elicits gastric irritation, juxtaglomerular apparatus (JGA) hypertrophy and hyperplasia and tubular degenerative changes in the kidney, and reduced red cell parameters and heart weights in rodents and/or dogs. Other manifestations of toxicity, including hepatic lesions in dogs, reduced offspring weights in rats, marked sensitivity of the rabbit, and clastogenic effects at cytotoxic doses in the in vitro V79 chromosome aberration assay, have been reported with other drugs of this class.

MATERIALS
Product Number
Brand
Product Description

Quinapril hydrochloride, European Pharmacopoeia (EP) Reference Standard
Quinapril for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Quinapril hydrochloride, ≥98% (HPLC), solid
Quinapril for peak identification, European Pharmacopoeia (EP) Reference Standard